Hui Wei
About Hui Wei
Hui Wei is the Associate Scientific Director/Analytical Team Lead at Bristol-Myers Squibb in Pennington, NJ, with a background in analytical chemistry and extensive experience in biologics discovery and development.
Current Role at Bristol-Myers Squibb
Hui Wei currently holds the position of Associate Scientific Director/Analytical Team Lead at Bristol-Myers Squibb in Pennington, NJ. In this role, Hui manages various analytical activities and oversees matrix teams composed of scientists and associate directors. Key responsibilities include leading high order structure characterization initiatives for biologics discovery and development, managing CMC activities, and authoring and reviewing important documents for IND and BLA filings. Hui also focuses on the hiring and coaching of team members to create highly effective analytical teams.
Previous Experience at Waters
Before joining Bristol-Myers Squibb, Hui Wei worked at Waters as a Senior MS Application Specialist and MS Applications Specialist II. Hui's tenure at Waters spanned from 2006 to 2010, during which Hui was based in Beverly, MA. This role entailed providing expertise and support in mass spectrometry applications, assisting in the development and troubleshooting of MS methodologies, and aiding in the integration of MS technologies in various projects.
Educational Background
Hui Wei has an extensive educational background in chemistry. Hui obtained a Ph.D. in Analytical Chemistry from the University of Michigan, where the focus was on advanced analytical techniques and methodologies. Prior to this, Hui earned a B.S. in Chemistry from the University of Science and Technology of China. This robust academic foundation laid the groundwork for Hui's subsequent professional achievements in the field of analytical chemistry.
Contributions to Biologics Discovery and Development
At Bristol-Myers Squibb, Hui Wei has contributed significantly to the biologics discovery and development departments. As the technology initiative lead, Hui spearheaded high order structure characterization projects, which are crucial for understanding and developing biologic drugs. Additionally, Hui played a key role in the preparation and review of regulatory documents, including IND and BLA filings, ensuring compliance and thoroughness in responses to health authority queries.